Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

CG Oncology, Inc. (CGON)

As of 2026-11-18 · 12/15 boxes filled from SEC filings and market data

Report price $78.94 (close 2026-11-17); latest close $79.47 (2026-11-20), +0.7% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -56% · upside -1%

The market is pricing CG Oncology at 984.33x EV/Sales on $6.2M of TTM revenue, a valuation that already assumes clinical and regulatory success rather than current sales. The call is PASS: the quality gate fails, with no evidenced moat, ROIC below WACC and a weak FCF yield. Downside is -55.9% to $34.84, from -30.0% sales at a compressed EV/Sales of 493.67x (today 984.33x). There is no base case: no comparable peer multiple sets one, no independent multiple (peer median or own history) was available, and a base at today's multiple is today's price by construction. Upside is 0.0% to $78.94, the analyst's own upside (no earnings change was given to price it). With only a downside and a flat upside, the risk/reward does not support a value purchase; this means not a value buy at this price, not a bad business.

Key numbers

  • Share price: $79.47
  • Market cap: $7.10B
  • Latest financial period: TTM to Sep 30, 2026
  • Revenue (TTM): $6.2M
  • FCF yield: -2.7%
  • Price / book: 7.17x
  • Revenue growth (latest fiscal year): +254.7%
  • ROIC (TTM): -1328.3%
  • WACC: 11.4%
  • Economic profit spread: -1339.7 pts

The 15 boxes

  1. ✓ 1. Long-form business notes

    CG Oncology is a single-asset, pre-commercial biopharma: revenue was only $204,000 in FY2023, $1.1M in FY2024, $4.0M in FY2025 and $6.2M for the TTM to 2026-09-30, against operating losses widening from -$55.4M to -$264.7M over the same spans, so the business is funded by equity, not operations. The economic case rests on one intravesical oncolytic immunotherapy, cretostimogene, in BOND-003 Cohort C for high-risk BCG-unresponsive NMIBC (75.5% CR at any time in 46 of 110 patients, June 23, 2025 cutoff), with a BLA begun in Q4 2025 and expected to be completed in 2026. Between the FY2023 and latest 10-K the story moved from 'topline by end of 2024' to a filed BLA, a completed PIVOT-006 enrollment, three more CORE-008 cohorts, and the start of an in-house U.S. commercial build. Cash plus short-term investments rose from $8.3M + $179.4M at FY2023 to $28.2M + $956.2M at the TTM to 2026-09-30, with diluted shares at 88.13M.

  2. ✓ 2. Competitive advantage

    No durable competitive advantage is demonstrated: CG Oncology is a single-asset Phase 3 developer with $6.2M TTM revenue against a $264.7M TTM operating loss and negative $187.3M TTM operating cash flow. Its only moat-like items are a regional Kissei license/supply arrangement and control of CMO Biovire, which is not profitable and was a new operating capability. It faces BCG and numerous larger oncology competitors with greater resources.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 revenue was $1.604 million versus $1.666 million a year earlier, all of it Biovire contract manufacturing; license and collaboration revenue fell to zero. Cost of sales ($2.669 million, Q3 2026) exceeded that revenue, R&D jumped 41% to $39.221 million on CMC spend and headcount, and G&A was flat at $22.963 million, producing a $63.249 million operating loss and a $56.891 million net loss ($(0.64) per share). Cash and marketable securities were $984.5 million at September 30, 2026, funded partly by $391.4 million of ATM net proceeds in the nine months, and the release says that funds operations through 2029. The pipeline calendar is the guidance: PIVOT-006 topline in November 2026, 12-month data from two cohorts in December 2026, BLA completion in Q4 2026.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans